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Natural killer (NK) cells express activating and inhibitory receptors, which recognize
MHC class-I alleles, termed “Killer cell Immunoglobulin-like Receptors” (KIRs). Preclin-
ical and clinical data from haploidentical T-cell-depleted stem cell transplantation have
demonstrated that alloreactive KIR-L mismatched NK cells play a major role as effectors
against acute myeloid leukemia (AML). Outside the transplantation setting, several reports
have proven the safety and feasibility of NK cell infusion in AML patients and, in some
cases, provided evidence that transferred NK cells are functionally alloreactive and may
have a role in disease control. The aim of the present work is to briefly summarize
the most recent advances in the field by moving from the first preclinical and clinical
demonstration of donor NK alloreactivity in the transplantation setting to the most recent
attempts at exploiting the use of alloreactive NK cell infusion as a means of adoptive
immunotherapy against AML. Altogether, these data highlight the pivotal role of NK cells
for the development of novel immunological approaches in the clinical management
of AML.
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Introduction
The clinical management of acute myeloid leukemia (AML) relies on aggressive chemotherapy,
followed by allogeneic stem cell transplantation (SCT). Although the post-chemotherapy complete
remission (CR) rate ranges from 60 to 85% in younger patients, the disease relapse is still very high,
thus reducing overall survival (OS) to 40%. Of note, the prognosis of elderly patients is particularly
poor with an OS of about 10%. Such a particular dismal clinical outcome is due to an increase in
unfavorable biological features, which reduces the CR rate and, whenever CR is obtained, to the
inability to undergo post-CR consolidation programs, including SCT, due to co-morbidities. In
the attempt to improve AML clinical outcome, novel regimens and targeted therapies have been
proposed in the last few years but the clinical results have proven limited. In particular, a minimal
residual disease (MRD), resistant to further treatments, often persists after induction chemotherapy.
In that context, the use of an immunological approach to target MRD may significantly impact on
the eradication of disease. The proof-of-principle of the capacity of immune cells to eradicate MRD
derives from the results of allogeneic SCT, which clearly represents an option for relapse prevention.
In particular, the critical role of natural killer (NK) cells as key players in AML prevention
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and eradication has been clearly established, especially in the
context of haploidentical SCT. However, the SCT approach has
important limitations and is not applicable to all patients. For
these reasons, it is conceivable to exploit the anti-leukemia poten-
tial of NK cells outside the transplantation setting as adoptive
immunotherapy.
NK Cells: Biological Pills
Within allogeneic SCT, donor lymphocytes recognize and destroy
the recipient’s residual leukemic cells. The demonstration that this
process, known as graft versus leukemia (GvL) effect, plays amajor
role in the therapeutic effect of SCT has led to the development
of novel strategies of adoptive immunotherapy before and after
SCT (1). Although most of the data refer to allogeneic T cells
as GvL mediators, it is known that other subsets of circulating
lymphocytes, such as NK cells, may significantly act as effector
cells against leukemia in the post-transplantation setting. NK
cells are defined by the expression of CD56 and CD16 and by
the absence of the T-cell marker, CD3. NK cells are involved in
the innate immune response and in cancer immunosurveillance,
where they kill transformed tumors in a major histocompati-
bility complex (MHC)-unrestricted manner (2). NK cells origi-
nate from the bone marrow (BM) and then home to secondary
lymphoid tissues. They account for 10–15% of peripheral blood
lymphocytes and their activity depends on the expression on
their surface of several activating and inhibitory receptors that
recognize MHC class-I molecules (Figure 1A); the most notable
inhibitory receptors are named killer cell immunoglobulin-like
receptors (KIRs), which recognize allotypic determinants within
certain groups of HLA class-I alleles. The lack of expression of
the specific HLA class-I allele by allogeneic target cells allows
KIRs to sense the absence of the self class-I KIR-ligand (KIR-L),
thusmediating NK alloreactivity. Indeed, the engagement of these
NK cell receptors results in stimulation or inhibition of NK cell
effector function. KIR genes are closely packed in the leukocyte
receptor complex on chromosome 19q13.4 and are inherited as
haplotypes. Two distinct KIR haplotypes have been identified.
Group A haplotypes encode inhibitory KIRs and have a fixed
gene content, whereas group B haplotypes are variable in num-
ber and combination. NK cells become functionally competent
only after they encounter self-HLA molecules during a process
named licensing or NK cell education. About 10–20% of NK
cells remain unlicensed and are hypo-responsive. Recently, other
inhibitory receptors on NK cells have been identified, such as
CD94/NKG2A receptors, that recognize a non-classicMHC class-
I molecule (HLA-E). CD94/NKG2A continuously recycles from
the cell surface through endosomal compartments, thus facilitat-
ing its inhibitory capacity (3). NK cells can also express activating
forms of KIRs and the activating receptor CD94/NKG2C that
interact with the same HLA molecules as their inhibitory coun-
terparts. Other activating receptors include natural cytotoxicity
receptors (NKp46, NKp30, NKp44), DNAM-1 that interacts with
CD112 and CD155, and NKG2D, which recognizes ligands, up-
regulated during cellular stress, such as tumor transformation
and viral infections (4). In addition, CD16 (FcgammaRIIIA) trig-
gers antibody-dependent cellular cytotoxicity on opsonized target
FIGURE 1 | (A) Receptors and ligand involved in NK cell-mediated
cytotoxicity. (B) Percentage of long-term CR patients after NK cell infusion.
Thirteen AML patients, five with active disease, two in molecular relapse, and
six in morphological complete remission (CR) were treated with alloreactive
NK cells, after fludarabine/cyclophosphamide immunosuppressive
chemotherapy. Only one of the five patients with active disease achieved
transient CR, whereas the other four patients had no clinical benefit. On the
contrary, five out of eight patients showed a response, which in some cases
was long-lasting CR [adapted from Curti et al. (5)].
cells, including tumor cells. Integrins also play a central role in
mediating adhesion to target cells and degranulation (4).
NK Cell Alloreactivity in Allogeneic SCT
Haploidentical Hematopoietic SCT
Although autologousNK cell activity is usually impaired in cancer
patients (6), allogeneic alloreactive NK cells from healthy donors
have been shown to exert important effector cell function and
could be safely infused in cancer patients without side effects
(7). In particular, within the setting of allogeneic SCT, the KIR-L
incompatibility between donor and recipient in the GvL direc-
tion has been demonstrated to enhance the anti-cancer efficacy
of NK cells, thus providing a novel and successful platform for
anti-tumor immunotherapy. In the setting of T-cell-depleted hap-
loidentical KIR-L mismatched SCT, we demonstrated that NK
cell alloreactivity mediates a powerful and protective GvL effect,
which is dissociated from Graft versus Host Disease (GvHD) (8).
Indeed, early after T-cell-depleted transplantation, the reconsti-
tuted NK cells represent the predominant lymphoid cell popula-
tion and the hematopoietic stem cells gave origin to an NK cell
repertoire, which is identical to the donor one (8–10). Of note,
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the GvL activity of donor NK cells is triggered when the donor’s
KIRs and the recipient’s HLA class-I molecules are incompatible,
and consequently when inhibitory signals in the recipient are
lacking. Preliminary studies in preclinical models demonstrated
that human alloreactiveNK clones, infused intoNOD/SCIDmice,
previously engrafted with human AML cells, are capable of clear-
ing leukemia cells and improving survival. These preclinical data
on the impact of donor NK cell alloreactivity were confirmed
in a series of more than 112 AML patients transplanted with
haploidentical donors. Patients were divided in two subgroups,
according to KIR-L incompatibility in the GvH direction. In
the group with KIR-L incompatibility a significantly reduced
relapse rate was observed. Moreover, 5-year event-free survival
was 5% in contrast to 60% observed in the group without KIR-L
incompatibility, thus demonstrating that KIR-L incompatibility
is the only independent predictive factor for survival in AML
patients. Furthermore, alloreactive mismatched NK cells facili-
tated hematopoietic engraftment after infusion of haploidentical
stem cells and inhibited GvHD by killing host antigen-presenting
cells (9). Of note, in our adult cohort of transplanted patients, NK
cell alloreactivity was not efficient in preventing disease relapse
of acute lymphoblastic leukemia (ALL). In contrast, in a group
of pediatric leukemia patients, including ALL, undergoing hap-
loidentical SCT, Pende et al. showed the beneficial role of acti-
vating KIRs and donor NK cell alloreactivity (11). Other clinical
studies support the protective role of alloreactive NK cells in
the haploidentical SCT setting. Stern et al. showed the results
of a phase II multicenter study in which purified NK cells were
administered pre-emptively in recipients of T-cell-depleted hap-
loidentical SCT. Sixteen young patients with high-risk leukemia or
highly malignant solid tumors were included in this protocol and
received NK-donor lymphocyte infusions (DLI) on days 40 and
100 after transplantation. This study demonstrated the feasibility
of the procedure. However, as a consequence of contaminating
T cells in NK-DLI cell preparation, the trial showed a high inci-
dence of acuteGvHD,whereas the anti-leukemic activity appeared
to be very limited (12). The use of allogeneic donor NK cells
instead of autologousNK cells for cancer therapy has been recently
reported. Several groups have explored allogeneic NK cells for the
treatment of relapse following HLA-haploidentical SCT. Interest-
ingly, GvHD did not occur. Some groups have infused activated,
expanded donor NK cells in patients early after allogeneic SCT.
Table 1 summarizes clinical trials with allogeneic NK cells as
therapeutics. In these studies, clinical responses were observed
in some patients and overall rates of relapse were reduced. For
patients lacking an HLA-identical donor and for those with pro-
gressive disease, the use of HLA-haploidentical family donors is
now increasingly considered to be a suitable alternative. How-
ever, many different protocols of T-cell-repleted haploidentical
transplantation are ongoing and few data are available on the role
of NK alloreactive donors in the presence of T cells in the graft
and/or when GvHD prophylaxis is administered. The results of
these studies are highly warranted to better elucidate the possible
competition of NK and T cells and the role of immune suppressive
drugs on NK cells in vivo.
Unrelated and Matched SCT
Unlike haploidentical SCT, the role of NK cell alloreactivity in
the field of unrelated SCT is controversial, even though several
studies have already investigated this setting (Table 2). Some
years ago Giebel et al. conducted a study involving 130 patients
with hematological malignancies who underwent allogeneic SCT
and received Cyclosporine, ATG and short-term methotrexate as
GvHD prophylaxis. With a median follow-up of 4.5 years, the OS
was 87% in patients with a KIR mismatch in the donor direc-
tion versus 48% in non-KIR-mismatched patients; disease-free
survival (DFS) was 87% in the first group compared with 39%
in the second one. Transplant-related mortality was 6% in the
KIR-mismatched patients and 40% in non-mismatched patients
(13). These results were not confirmed in studies published by
other centers (14, 15), which showed a detrimental effect of KIR-L
incompatibility, correlated with HLA mismatching. These con-
troversial data demonstrated that the role of NK cells remains
unclear in the setting of unrelated SCT. Several factors, such as
post-transplantation immunosuppressive therapies, T-cell deple-
tion, different stem cell sources and doses, may impact in this
patient setting (13–15). In a group of donor-recipient pairs miss-
ing an inhibitory KIR-L, a beneficial role of alloreactive NK cells,
transiently and randomly originated from donor stem cells, was
observed (16). These cells expressed the inhibitory single KIR
receptor that could not be blocked by the host cells. However,
these alloreactiveNK cells were not functional, thus corroborating
TABLE 1 | Clinical trials with expanded allogeneic NK cells in haploidentical SCT.
Diseases Phase of trials Cells Combined therapy Institute




Hematological malignancies Ongoing Phase-1 IL-2-activated NK cells Haploidentical HSCT and RIC Institut Paoli-Calmette, France
Leukemia and
myeloproliferative disease
Ongoing phase 1/2 Haploidentical HSCT, TBI and
chemotherapy
Ex vivo expanded NK cells M.D. Anderson Cancer
Center, USA






AML and ALL Ongoing phase 1/2 Ex vivo expanded NK-cells haploidentical HSCT Asan Medical Center, Korea
Relapsed/refractory
pediatric acute leukemia
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TABLE 2 | Themost relevant papers reporting the impact of KIR-Lmismatch
in unrelated SCT.
Authors Survival TRM Relapse GvHD ATG
Davies et al. (14) # Not assessed ! "a,b No
Giebel et al. (13) " # #a #a,c Yes
Bornhäuser et al. (15) ! ! " ! Yes
Malmberg et al. (17) # " ! ! Yes
aTrend, P-value between 0.05 and 0.09.
bGvHD grade II–IV.
cGvHD grade III–IV.
the notion that NK cells must be educated and consequently
armed by the presence of the appropriate inhibitory KIR-L (17).
New data have been provided on the possible role of activat-
ing KIRs which are present on KIR B haplotypes. Cooley et al.
showed that B haplotype, which is present in 60% of donors, is
fundamental in preventing relapse while NK cell alloreactivity
does not influence the outcome of a very large cohort of unre-
lated transplants (18). However, in the setting of T-cell-depleted
haploidentical transplants, the presence of KIR B haplotypes is
associated with reduced infection-related mortality in the group
of patients transplanted from NK alloreactive donors without any
impact on relapse (19).
Alloreactive NK Cells as Adoptive
Immunotherapy
Natural killer cells have already been used as a means of adop-
tive immunotherapy beside the SCT setting (16, 20). These
studies reported on the trafficking and body distribution of
infused NK cells. Based on these preliminary data, NK cell selec-
tion for immunotherapy has recently been developed at clin-
ical level (21). In 2005, Miller et al. published the results of
a seminal study in which up to 1.5 107/haploidentical NK
cells/kg were safely infused in AML and cancer patients follow-
ing Fludarabine/Cyclophosphamide (Flu/Cy) immunosuppres-
sive chemotherapy; in this study some clinical responses without
GvHD were observed. Circulating haploidentical NK cells were
found up to 28 days after infusion, especially when exogenous
interleukin (IL)-2 was given. In vivo expansion of NK cells was
correlated with a high IL-15 serum concentration. In partic-
ular, 19 poor risk AML patients, together with 10 metastatic
melanoma patients and 13metastatic renal cell carcinoma patients
received a cell population enriched in NK cells. Five out of 19
AML patients achieved CR, NK cell adoptive immunotherapy
was well tolerated and no hematological toxicity was recorded.
The maximum tolerated dose of NK cells was not achieved and
GvHD was not observed despite the relatively high number of
infused haploidentical T cells. However, it should be noted that
NK cells were only partially purified after a single round of
depletion of CD3+ cells which resulted in less than a 2 log
reduction of T cells (21). A group of 10 low-risk pediatric AML
patients were treated with haploidentical KIR–HLA mismatched
NK infusion. All patients were alive at the 2-year follow-up.
As compared to the adult trial by Miller’s group, the median
number of infused NK cells was significantly higher and NK
cells were processed to obtain a highly purified cell population
(22). We reported the results of a trial of NK cell-based adoptive
immunotherapy in 13 AML patients, 5 with active disease, 2 in
molecular relapse, and 6 in morphological CR. The median age
was 62 years (range 53–73). Highly purified CD56+CD3- NK
cells from haploidentical KIR-ligand mismatched donors were
infused after fludarabine/cyclophosphamide immunosuppressive
chemotherapy. No signs of GvHD and/or NK cell-related toxicity
were reported. As expected, patients with active disease had no
clinical benefit. Interestingly, both patients in early molecular
relapse achieved CR and three patients in CR were disease-free
after a follow-up of 34, 32, and 18months of followup (Figure 1B).
Infused NK cells were detected in the peripheral blood of all
evaluable patients and in the BM in some cases. Importantly,
infused NK cells were demonstrated ex vivo to be alloreactive
by killing in vitro the recipient’s cells, including leukemia (5).
Several biological factors, both of recipient and donor origin, may
be implicated in the therapeutic effect of NK cells after infusion
into AML patients. Miller and collaborators recently reported on
the critical impact of some components of the recipient immune
response on the anti-leukemia activity of infused NK cells (23).
In particular, they reported NK cell expansion correlates with
the post-chemotherapy serum concentrations of some cytokines,
such as IL-15 and IL-35, and the number of T regulatory cells
(Tregs) critically influences the capacity of infused NK cells to
expand and to kill AML cells. The clinical relevance of these
findings is supported by a better DFS in patients undergoing
NK immunotherapy and depleted of Tregs. As for the donor,
it would be interesting to test whether the composition of the
donor NK cell population may be correlated to a different clin-
ical outcome. In particular, the frequency and the function of
alloreactive NK cells may impact on the anti-leukemia capacity
of infused NK cells. Moreover, the presence within the graft of
different subsets of CD56+ cells, other than “classic” NK cells,
should be evaluated in more detail and, possibly, correlated with
the response to NK therapy. The manipulation of donor NK
cell graft may represent an interesting approach to increase NK
cell activity before infusion. This is a critical point since NK
cell-based immunotherapy may be significantly hampered by the
transient effector function of infused NK cells. In particular,
in vitro priming with cytokines, such as IL-12, IL-18, and IL-15,
has been reported. This treatment results in the expansion of the
memory-like NK cell subset with enhanced functional properties
(24) and more prolonged persistence in the host. (25). Recently,
in a mouse tumor model a cytokine-based treatment resulted in
enhanced anti-tumor activity via the reversal of NK cell anergy,
which occurs in the presence of MHC-deficient tumors (26).
Since HLA-loss is known to be a fundamental immune escape
means for adaptive T-cell-mediated immune response (27), pre-
venting NK-cell anergy may have important clinical implications
for cancer immunotherapy.
Conclusions
Alloreactive NK cells have been emerging as a potent effector
cell population against AML. The demonstration of a significant
clinical activity of alloreactive purified NK cell infusion outside
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the transplantation setting represents a proof-of-principle for such
an anti-leukemia effect, which has been clearly established in the
context of haploidentical SCT. Altogether, these data highlight the
pivotal role of NK cells for the development of novel immunologi-
cal approaches in the clinical management of AML. Nevertheless,
several biological issues still require full elucidation. In particular,
a more in-depth evaluation of the impact that recipient- and
donor-derived factors may have in influencing in vivo NK cell
activity is an important point. The design of future NK cell-based
clinical trials, both in the SCT and adoptive immunotherapy set-
tings, should include a correlation between clinical results and bio-
logical outputs. Indeed, correlative biological studies may make
it possible to identify those subsets of patients, who may really
benefit from NK immunotherapy, in the attempt to tailor both
pharmacological and immunological therapies to the patients’
characteristics.
References
1. Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, et al. Pre-
emptive immunotherapy with purified natural killer cells after haploidentical
SCT: a prospective phase II study in two centers. Bone Marrow Transplant
(2013) 48:433–8. doi:10.1038/bmt.2012.162
2. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene
(2008) 27:5932–43. doi:10.1038/onc.2008.267
3. Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of
the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol
(2005) 42:485–8. doi:10.1016/j.molimm.2004.07.031
4. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future
directions. J Allergy Clin Immunol (2013) 132:536–44. doi:10.1016/j.jaci.2013.
07.006
5. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, et al. Successful
transfer of alloreactive haploidentical KIR ligand-mismatched natural killer
cells after infusion in elderly high risk acute myeloid leukemia patients. Blood
(2011) 118:3273–9. doi:10.1182/blood-2011-01-329508
6. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-
directed therapies: moving from unexpected results to successful strategies.Nat
Immunol (2008) 9:486–94. doi:10.1038/ni1580
7. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current
insights and future prospects. J Intern Med (2009) 266:154–81. doi:10.1111/j.
1365-2796.2009.02121.x
8. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role
of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell
transplantation. Blood (1999) 94:333–9.
9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A,
et al. Effectiveness of donor natural killer cell alloreactivity in mismatched
hematopoietic transplants. Science (2002) 295:2097–100. doi:10.1126/science.
1068440
10. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al.
Donor natural killer cell allorecognition of missing self in haploidentical
hematopoietic transplantation for acute myeloid leukemia: challenging
its predictive value. Blood (2007) 110:433–40. doi:10.1182/blood-2006-07-
038687
11. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D,
et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched
haploidentical HSCT for pediatric patients: evaluation of the functional role
of activating KIR and redefinition of inhibitory KIR specificity. Blood (2009)
113:3119–29. doi:10.1182/blood-2008-06-164103
12. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, et al.
Purified donor NK-lymphocyte infusion to consolidate engraftment after hap-
loidentical stem cell transplantation. Leukemia (2004) 18:1835–8. doi:10.1038/
sj.leu.2403524
13. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al.
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell
transplantation from unrelated donors. Blood (2003) 102:814–9. doi:10.1182/
blood-2003-01-0091
14. Davies SM, Ruggieri L, DeFor T,Wagner JE,Weisdorf DJ, Miller JS, et al. Evalu-
ation of KIR ligand incompatibility inmismatched unrelated donor hematopoi-
etic transplants. Killer immunoglobulin-like receptor.Blood (2002) 100:3825–7.
doi:10.1182/blood-2002-04-1197
15. Bornhäuser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C,
Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem
cell transplantation using unrelated donors. Blood (2004) 103:2860–1.
doi:10.1182/blood-2003-11-3893
16. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD, et al.
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell
transplantation for hematologic malignancy. Biol Blood Marrow Transplant
(2006) 12:828–36. doi:10.1016/j.bbmt.2006.04.008
17. Malmberg KJ, Schaffer M, Ringdén O, Remberger M, Ljunggren HG. KIR-
ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol
Immunol (2005) 42:531–4. doi:10.1016/j.molimm.2004.07.037
18. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al.
Donor selection for natural killer cell receptor genes leads to superior survival
after unrelated transplantation for acute myelogenous leukemia. Blood (2010)
116:2411–9. doi:10.1182/blood-2010-05-283051
19. Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, et al. Hap-
loidentical hematopoietic transplantation fromKIR ligand-mismatched donors
with activating KIRs reduces nonrelapse mortality. Blood (2015) 125:3173–82.
doi:10.1182/blood-2014-09-599993
20. Meller B, Frohn C, Brand JM, Lauer I, Schelper LF, von Hof K. Monitoring
of a new approach of immunotherapy with allogeneic In-labelled NK cells in
patients with renal cell carcinoma.Eur JNuclMedMol Imaging (2004) 31:403–7.
doi:10.1007/s00259-003-1398-4
21. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch
SK, et al. Successful adoptive transfer and in vivo expansion of human hap-
loidentical NK cells in patients with cancer. Blood (2005) 105:3051–7. doi:10.
1182/blood-2004-07-2974
22. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a
pilot study to determine the safety and feasibility of haploidentical natural killer
cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010)
28:955–9. doi:10.1200/JCO.2009.24.4590
23. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al.
Clearance of acute myeloid leukemia by haploidentical natural killer cells is
improved using IL-2 diphtheria toxin fusion protein.Blood (2014) 123:3855–63.
doi:10.1182/blood-2013-10-532531
24. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP,
et al. Cytokine activation induces human memory-like NK cells. Blood (2012)
120:4751–60. doi:10.1182/blood-2012-04-419283
25. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function
of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med
(2012) 209:2351–65. doi:10.1084/jem.20120944
26. Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, et al.
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin
Invest (2014) 124:4781–94. doi:10.1172/JCI74337
27. Vago L, Perna SK, Zanussi M,Mazzi B, Barlassina C, Stanghellini MT, et al. Loss
of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med
(2009) 361:478–88. doi:10.1056/NEJMoa0811036
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Ruggeri, Parisi, Urbani and Curti. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org October 2015 | Volume 6 | Article 4795
